COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01023776
Recruitment Status : Completed
First Posted : December 2, 2009
Results First Posted : December 23, 2015
Last Update Posted : December 23, 2015
Information provided by (Responsible Party):
John Treanor, University of Rochester

Brief Summary:
The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.

Condition or disease Intervention/treatment Phase
Influenza Biological: A/California/07/09 live monovalent H1N1 vaccine Phase 4

Detailed Description:
By looking at the immune response before and after vaccine, we hope to understand the factors that determine the immune response and detailed shedding patterns of live novel H1N1 vaccine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Evaluation of the Infectivity, Replication, and Immunogenicity of Live, Attenuated A/California/07/09 (nH1N1) Influenza Vaccine in Serosusceptible Adults
Study Start Date : November 2009
Actual Primary Completion Date : April 2010
Actual Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
live monovalent H1N1 vaccine
A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
Biological: A/California/07/09 live monovalent H1N1 vaccine
0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
Other Name: Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Primary Outcome Measures :
  1. Number of Participants Who Shed Virus [ Time Frame: 28 days post vaccine 1 and 28 days vaccine 2 ]
    number of participants who shed virus above the limit of detection at any timepoint after vaccine. The limit of detection is 0.5 tissue culture infectious doses per mL of nasal wash.

Secondary Outcome Measures :
  1. Mean Difference Between Cycle Time and Detection Threshold [ Time Frame: day 10 post vaccine 1 ]
    The mean difference was calculated by real-time polymerase chain reaction (PCR) on nasal wash samples. Cycle time is the cycle number at which the PCR reaction is positive with a range of 0-40 cycles. The detection threshold is 40 cycles.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 32 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged 18-32 years, inclusive
  • No history of Novel H1N1 virus or vaccine
  • Female not able to bear children or not pregnant and agrees to practice effective birth control
  • Female negative pregnancy test
  • Good Health
  • Ability to understand and comply with protocol
  • Provided Informed Consent

Exclusion Criteria:

  • Previous history of vaccination against novel H1N1 or laboratory documented H1N1 infection
  • History of egg allergy or is allergic to other components of the vaccine
  • A women who is pregnant or breastfeeding or intends to get pregnant during the study period between enrollment and 30 days following vaccination
  • Subject is immunosuppressed as the result of underlying illness or treatment with immunosuppressive or cytotoxic drugs or use of chemotherapy or radiation therapy in the preceding 36 months
  • Subject has active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy. "active is defined as treatment within the past 5 years
  • Long term (greater than 2 weeks) use of oral or parental steroids, or high- dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids allowed)
  • Received immunoglobulin or another blood product within 3 months prior to enrollment in this study
  • Subject has received an inactivated vaccine within 2 weeks or a live vaccine within 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days (or 56 days for the vaccine naive recipients)
  • Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. Those conditions include chronic conditions recognized as risk factors for influenza complications or as contraindicated for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment
  • Subject has an acute illness or an oral temperature greater then 99.9 degrees F(37.7 C)within 3 days prior to enrollment or vaccination. Subject who has acute illness that was treated, symptoms resolved are eligible to enroll as long as treatment is complete and symptoms resolved > 3 dyas prior to enrollment.
  • Subject is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or intends to donate blood during this period.
  • Subject has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
  • Subject has a history of alcohol or drug abuse in the 5 years prior to enrollment.
  • Subject has known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
  • Subject has a previous history of Guillain-Barre syndrome within 6 weeks of receipt of influenza vaccine
  • Subject has any condition that the principal investigator (PI) believes may interfere with the successful completion of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01023776

Layout table for location information
United States, New York
Vaccine Research Unit Room 3-5000
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Layout table for investigator information
Principal Investigator: John J. Treanor, M.D. University of Rochester
Layout table for additonal information
Responsible Party: John Treanor, M.D., University of Rochester Identifier: NCT01023776    
Other Study ID Numbers: URMC 09-006
First Posted: December 2, 2009    Key Record Dates
Results First Posted: December 23, 2015
Last Update Posted: December 23, 2015
Last Verified: November 2015
Keywords provided by John Treanor, University of Rochester:
Swine Flu
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs